JID Journal Supplement: Tuberculosis Drug Development

Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis

Volume 211 suppl 3 June 15, 2015

Click here for access to supplement


  • Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen Development J Infect Dis. (2015) 211 (suppl 3): S81-S82 doi:10.1093/infdis/jiv072
More News
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...